Home › Funds › Bellevue Group AG › DMRA
Bellevue Group AG position in DMRA
DAMORA THERAPEUTICS INC COM SHS · Health Care
Bellevue Group AG reported holding 1,618,846 shares of DMRA (DAMORA THERAPEUTICS INC COM SHS) in its Q2 2026 13F filing — a position valued at US$42.1M, representing 0.89% of its reported portfolio and ranking #32 among its reported holdings. Bellevue Group AG has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's DMRA position evolved
Bellevue Group AG first disclosed a stake in DMRA in Q1 2026 at 2,298,000 shares (US$59.5M). Across 2 filings, Bellevue Group AG increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,618,846 shares valued at US$42.1M — a reduction of -679,154 shares quarter over quarter.. Notable position changes include a 30% trim in Q2 2026 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.30M | $59.52M | New |
| Q2 2026 | 1.62M | $42.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (DAMORA THERAPEUTICS INC COM SHS) is a Health Care company. 105 other funds we track also report a position in DMRA — the largest reported positions include Fairmount Funds Management LLC (US$226.6M), Avoro Capital Advisors LLC (US$98.4M), Venrock Adviser, LLC (US$93.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Fairmount Funds Management LLC 8.71M sh · $226.63M · Q2 2026
- Avoro Capital Advisors LLC 3.78M sh · $98.40M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $63.49M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- Remedium Capital Partners, LLC 2.05M sh · $53.20M · Q2 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
- Vestal Point Capital, LP 575.00K sh · $14.96M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held DMRA?
Bellevue Group AG has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Bellevue Group AG's current position in DMRA?
As of Q2 2026, Bellevue Group AG holds 1.62M shares of DMRA (DAMORA THERAPEUTICS INC COM SHS), valued at $42.11M, representing 0.89% of its reported portfolio and ranking #32.
Has Bellevue Group AG been buying or selling DMRA?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in DMRA.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.